Voorbeelden van het gebruik van Patients aged in het Engels en hun vertalingen in het Nederlands
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Computer
-
Ecclesiastic
-
Official/political
-
Programming
Zonegran must be added to existing therapy for paediatric patients aged 6 years and above.
The pharmacokinetics of lurasidone in paediatric patients aged 6-17 years was generally comparable to those observed in adults.
Table 1: Dosing for paediatric patients aged 2 to< 12 years.
Heart failure(HF) is a prevalent disease affecting 1-3% of the general population and up to 20% of patients aged 80 and older.
in adolescent and paediatric patients aged 6 years and above.
The standard dose of Cystadane for patients aged over 10 years is 6 g a day, divided into two equal doses.
by body weight for paediatric patients aged 12-17 years.
In the second main study involving 341 patients aged over 12 years, PAS in combination with isoniazid was compared with isoniazid alone.
The CHMP considered that Reyataz's effectiveness had been shown in patients aged at least 3 months and weighing at least 5 kg.
Sebelipase alfa has not been investigated in patients 2 to 4 years of age or patients aged 65 years or older.
is much more common among patients aged 65 or over.
HIV-infected paediatric patients aged 3 months to 17 years were enrolled in the ARROW Trial(COL105677),
Renal adverse reactions consistent with proximal renal tubulopathy have been reported in HIV-1 infected paediatric patients aged 2 to< 12 years in clinical study GS-US-104-0352 see sections 4.8 and 5.1.
Patients aged over 65 years Studies in patients over the age of 65 have not been performed and no dosage regimen can presently be
The safety assessment in children is based on the safety data from 2 trials in which 227 paediatric patients aged from 2 months to 17 years with cSSTI or CAP received Zinforo.
Patients aged over 65 years should start with a 1 mg dose once a day,
The safety of Genvoya in HIV-1 infected, treatment-naïve paediatric patients aged 12 to< 18 years was evaluated through 48 weeks in an open-label clinical study GS-US-292-0106.
in the small number of patients aged over 80 years who did not have any protection against the virus at the start of the study.
with only 2 patients aged 65 years of age or older.
For paediatric dosing information for patients aged 2-12 years, see Summary of Product Characteristics